Around four million people in the UK live with an autoimmune condition, according to a major study published in The Lancet.

Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 - ...

In a comprehensive study, researchers from the Department of Epidemiology at the Faculty of Medicine at the University of ...

Novartis announces both ianalumab phase III trials meets primary endpoint in patients with Sjögren’s disease: Basel Tuesday, August 12, 2025, 14:00 Hrs [IST] Novartis announced ...

The open-label trial aims to assess the therapy’s impact on clinical outcomes, microglial activation, and safety in this ...

Ianalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids1,2 Patients ...

Former Teva North America CEO Sven Dethlefs, PhD, to lead Celea PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated ...

Net income of $1.6 million and $5.3 million for the three and six months ended June 30, 2025, respectively; reaffirms full-year revenue guidance of $118-128 million ...

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System AtrophyNEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a ...

Using data from over 1.5 million patients from 47 studies, the researchers analysed the association between four autoimmune ...

Net income of $1.6 million and $5.3 million for the three and six months ended June 30, 2025, respectively; reaffirms full-year revenue guidance of $118-128 million Ping Zhang, Executive Chairman ...

Reports Q2 revenue $20.9M, consensus $12.92M. “We are encouraged by AUCATZYL’s early launch performance in the U.S., driven by physician ...